Canoa Inc. to Acquire Privately-Held ProSolus Inc., Accelerating Transdermal Patch Drug Delivery Product Development MIAMI, Florida, August 02, 2019 – Canoa Inc. (“Canoa”), a Delaware corporation with a focus on healthcare and pharmaceuticals, today announced that it has agreed to acquire ProSolus® Inc. (“ProSolus”), from Mission Pharmacal® Company, in an all-cash transaction. ProSolus is a…Details
ProSolus Seeks Higher Utilization of Transdermal Drug Delivery TechnologyParent company, Mission Pharmacal, expands commitment to patch technology with significant investments in manufacturing and commercial team. Transdermal patch production line at ProSolus, Inc. in Miami Juan Mantelle, ProSolus Chief Operating Officer and Chief Scientific Officer MIAMI, Fla. (April 25, 2017) – ProSolus, Inc. (“ProSolus”) is doubling…Details
We’re excited to share that Juan Mantelle, COO of ProSolus, Inc., is featured in the 2016 PharmaVOICE 100 issue, in the Commanders & Chiefs section. Congratulations Juan! The PharmaVoice 100 is a list of inspirational leaders, representing a wide range of industry sectors and functional areas, who are having an extraordinary and positive impact on…Details
Acquisition adds cutting-edge expertise in transdermal drug development and manufacturing SAN ANTONIO, TX — Effective May 29, 2015, Mission Pharmacal Company (“Mission”) has acquired the assets of ProSolus Pharmaceuticals LP headquartered in Miami, Fla. Mission’s wholly-owned subsidiary, ProSolus Inc., offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal (through the skin) drug…Details
ProSolus, Inc. is proud to announce the upcoming launch of LidoFlex, developed in conjunction with Mission Pharmacal and Richmar. LidoFlex has a 4% Lidocaine concentration, which is the highest concentration available without a prescription.